GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Farmaceutica Remedia SA (BSE:RMAH) » Definitions » Debt-to-EBITDA

Farmaceutica Remedia (BSE:RMAH) Debt-to-EBITDA : 0.15 (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Farmaceutica Remedia Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Farmaceutica Remedia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was lei2.4 Mil. Farmaceutica Remedia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was lei0.0 Mil. Farmaceutica Remedia's annualized EBITDA for the quarter that ended in Sep. 2023 was lei16.2 Mil. Farmaceutica Remedia's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Farmaceutica Remedia's Debt-to-EBITDA or its related term are showing as below:

BSE:RMAH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.13   Max: 0.43
Current: 0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Farmaceutica Remedia was 0.43. The lowest was 0.02. And the median was 0.13.

BSE:RMAH's Debt-to-EBITDA is ranked better than
88% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs BSE:RMAH: 0.16

Farmaceutica Remedia Debt-to-EBITDA Historical Data

The historical data trend for Farmaceutica Remedia's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Farmaceutica Remedia Debt-to-EBITDA Chart

Farmaceutica Remedia Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.36 0.02 0.14 0.11

Farmaceutica Remedia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.07 0.09 0.07 0.15

Competitive Comparison of Farmaceutica Remedia's Debt-to-EBITDA

For the Medical Distribution subindustry, Farmaceutica Remedia's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farmaceutica Remedia's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's Debt-to-EBITDA falls into.



Farmaceutica Remedia Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Farmaceutica Remedia's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.199 + 0) / 11.237
=0.11

Farmaceutica Remedia's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.386 + 0) / 16.232
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Farmaceutica Remedia  (BSE:RMAH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Farmaceutica Remedia Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Farmaceutica Remedia's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Farmaceutica Remedia (BSE:RMAH) Business Description

Traded in Other Exchanges
N/A
Address
No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.

Farmaceutica Remedia (BSE:RMAH) Headlines

No Headlines